Clinical Trial Update: Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MK-0524A (extended-release niacin/laropiprant) added to ongoing lipid-modifying therapy in patients with primary hypercholesterolemia o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• MK-0524A (Extended Release Niacin/Laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2014-03-14